Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy

Abstract

Objective

To assess the cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy (CIPN) in Hong Kong.

Methods

A within trial cost-utility analysis with the primary endpoint for the economic evaluation being the Quality Adjusted Life Year (QALY) and associated Incremental Cost Effectiveness Ratio (ICER) over 14 weeks of treatment. A secondary cost-effectiveness analysis was undertaken with the endpoint being change in pain as measured on the Brief Pain Inventory (BPI).

Results

Eighty-seven patients were randomised to acupuncture or usual care. Acupuncture resulted in significant improvements in pain intensity (8- and 14-week mean changes compared to usual care of −1.8 and −1.8, respectively), pain interference (8- and 14-week mean changes compared to usual care of −1.5 and −0.9, respectively) and indicators of quality of life and neurotoxicity-related symptoms. However, in the economic evaluation there was little difference in QALYs between the two arms (mean change 0.209 and 0.200 in the acupuncture and usual care arms, respectively). Also, costs yielded deterministic ICERs of HK$616,965.62, HK$824,083.44 and HK$540,727.56 per QALY gained from the health care provider perspective, the societal perspective and the patient perspective, respectively. These costs are significantly higher than the cost-effectiveness threshold of HK$180,450 that was used for the base case analysis.

Conclusion

While acupuncture can improve symptoms and quality of life indicators related to CIPN, it is unlikely to be a cost-effective treatment for CIPN-related pain in health care systems with limited resources.

Trial registration number

NCT02553863 (ClinicalTrials.gov) post-results.

Keywords

acupuncture chemotherapy cost-effectiveness peripheral neuropathy

Get full access to this article

View all access options for this article.

References

Liu

Skinner

McDonough

, et al. Acupuncture for low back pain: an overview of systematic reviews. Evid Based Complement Alternat Med 2015; 2015: 328196.

Pang

Jiang

, et al. Acupuncture for functional dyspepsia: what strength does it have? A systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2016; 2016: 3862916.

Linde

Allais

Brinkhaus

, et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016; 6: CD001218.

Ernst

Acupuncture: what does the most reliable evidence tell us?

J Pain Symptom Manage 2009; 37(4): 709–714.

Ambrosio

Bloor

MacPherson

Costs and consequences of acupuncture as a treatment for chronic pain: a systematic review of economic evaluations conducted alongside randomised controlled trials.

Complement Ther Med 2012; 20(5): 364–374.

Kim

Lee

Chae

, et al. A systematic review of cost-effectiveness analyses alongside randomised controlled trials of acupuncture. Acupunct Med 2012; 30(4): 273–285.

Stamuli

Bloor

MacPherson

, et al. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care. BMC Gastroenterol 2012; 12: 149.

Taylor

Pezzullo

Grant

, et al. Cost-effectiveness of acupuncture for chronic nonspecific low back pain. Pain Pract 2014; 14(7): 599–606.

Reinhold

Roll

Willich

, et al. Cost-effectiveness for acupuncture in seasonal allergic rhinitis: economic results of the ACUSAR trial. Ann Allergy Asthma Immunol 2013; 111(1): 56–63.

10.

Postma

Heimans

JJ.

Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000; 11: 509–513.

11.

Ocean

Vahdat

LT.

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004; 12(9): 619–625.

12.

Armstrong

Almadrones

Gilbert

MR.

Chemotherapy-induced peripheral neuropathy.

Oncol Nurs Forum 2005; 32(2): 305–311.

13.

Shimozuma

Ohashi

Takeuchi

, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 2012; 20(12): 3355–3364.

14.

Pike

Birnbaum

Muehlenbein

, et al. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012; 2012: 913848.

15.

Franconi

Manni

Schroder

, et al. A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med 2013; 2013: 516916.

16.

Molassiotis

Suen

LKP

Cheng

, et al. A randomized assessor-blinded wait-list controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Integr Cancer Ther 2019; 18: 1534735419836501.

17.

Cleeland

Gonin

Hatfield

, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330(9): 592–596.

18.

Huang

Brady

Cella

, et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007; 17(2): 387–393.

19.

Cheung

Thumboo

Gao

, et al. Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index. Value Health 2009; 12(2): 371–376.

20.

Glick

Doshi

Sonnad

, et al. Economic evaluation in clinical trials. Oxford: Oxford University Press, 2014.

21.

Hospital Authority. 2017 Fees and Charges. Hong Kong, http://www.ha.org.hk/visitor/ha_visitor_text_index.asp?Parent_ID=10044&Content_ID=10045&Ver=TEXT (accessed December 2018).

22.

Drummond

Sculpher

MJC

laxton

, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2015.

23.

Bertram

MYL

Lauer

De Joncheere

, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 2016; 94(12): 925–930.

24.

Woods

Revill

Sculpher

, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health 2016; 19(8): 929–935.

25.

Claxton

Martin

Soares

, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015; 19(14): 1–5403. https://doi.org/10.3310/hta19140

26.

Ramsey

Willke

RJG

Glick

, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR good research practices task force report. Value Health 2015; 18(2): 161–172.

27.

Faria

Gomes

Epstein

, et al. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics 2014; 32(12): 1157–1170.

28.

O’Brien

Briggs

AH.

Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.

Stat Methods Med Res 2002; 11(6): 455–468.

29.

Briggs

O’Brien

Blackhouse

Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.

Annu Rev Public Health 2002; 23: 377–401.

30.

Thokala

Ochalek

Leech

AA.

Cost-effectiveness thresholds: the past, the present and the future.

Pharmacoecon 2018; 36: 509–522.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB